Company news

Editas Medicine, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events

May 1, 2024

Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration

April 30, 2024

Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting

April 21, 2024

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates

February 27, 2024

Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events

February 20, 2024

Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference

January 7, 2024

Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

January 2, 2024

Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9

December 12, 2023

Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar

December 10, 2023

Editas Medicine Announces Third Quarter 2023 Results and Business Updates

November 2, 2023

Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar

November 1, 2023

Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events

October 26, 2023

Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease

October 15, 2023

Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer

September 24, 2023

Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer

September 24, 2023

Editas Medicine Announces Upcoming Investor Events

August 29, 2023

Editas Medicine Announces Second Quarter 2023 Results and Business Updates

August 1, 2023

Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas' Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization

July 26, 2023

Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update

July 25, 2023

Editas Medicine Reports Inducement Grant to New Chief Scientific Officer

July 24, 2023

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer

July 23, 2023

Editas Medicine Announces Pricing of Offering of Common Stock

June 13, 2023

Editas Medicine Announces Offering of Common Stock

June 13, 2023

Editas Medicine Announces Positive Initial EDIT-301 Safety and Efficacy Data from the First Four Patients Treated in the RUBY Trial and the First Patient Treated in the EdiTHAL Trial

June 8, 2023

Editas Medicine to Host Virtual Event to Discuss EDIT-301 Clinical Data from the RUBY Trial for Severe Sickle Cell Disease and the EDITHAL Trial for Transfusion-dependent Beta Thalassemia

June 5, 2023

Editas Medicine Reports Inducement Grant to New Chief Financial Officer

May 17, 2023

Editas Medicine Announces Appointment of Erick J. Lucera as Chief Financial Officer

May 15, 2023

Editas Medicine to Present Clinical Data from the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease at the EHA 2023 Congress

May 10, 2023

Editas Medicine Announces First Quarter 2023 Results and Business Updates

May 4, 2023

Editas Medicine Announces Publication in Nature Biotechnology of Comprehensive SLEEK Gene Editing Technology Data

April 30, 2023

Editas Medicine Announces First Quarter 2023 Results Conference Call and Upcoming Investor Events

April 30, 2023

Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Sickle Cell Disease

April 26, 2023

Editas Medicine Strengthens Board of Directors with Appointment of New Chair and New Director

April 12, 2023

Editas Medicine Strengthens Executive Leadership Team with Appointment of Linea Aspesi as Chief People Officer

March 7, 2023

Editas Medicine Announces Fourth Quarter and Full Year 2022 Results and Business Updates

February 21, 2023

Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2022 Results and Corporate Update

February 14, 2023

Editas Medicine and Shoreline Biosciences Enter into Definitive Agreement for Shoreline to Acquire Editas’ iNK Cell Franchise and Related Gene Editing Technologies

January 18, 2023

Editas Medicine Announces Strategic Updates and Portfolio Reprioritization

January 8, 2023

Editas Medicine to Present at the 41st Annual J.P. Morgan Healthcare Conference

January 3, 2023

Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease

December 5, 2022

Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease

November 30, 2022

Editas Medicine Announces Clinical Data Demonstrating Proof of Concept of EDIT-101 from Phase 1/2 BRILLIANCE Trial

November 16, 2022

Editas Medicine Announces Third Quarter 2022 Results and Business Updates

November 1, 2022

Editas Medicine to Host Conference Call Discussing Third Quarter 2022 Results and Corporate Update

October 25, 2022

Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the European Society of Gene and Cell Therapy Annual Meeting

October 12, 2022

Editas Medicine Announces Second Quarter 2022 Results and Business Updates

August 2, 2022

Editas Medicine Announces Clinical Achievements in the Development of EDIT-301 for Sickle Cell Disease

July 26, 2022

Editas Medicine to Host Conference Call Discussing Second Quarter 2022 Results and Corporate Updates

July 25, 2022

Editas Medicine Reports Inducement Grant to New Chief Medical Officer

July 19, 2022

Editas Medicine Appoints Baisong Mei, M.D., Ph.D., as Chief Medical Officer

July 17, 2022

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 25 decks. Every deck is listed under its year.